IL1RL1
ENSG00000115602
Target class
Enzyme
Chromosome
2
Approved drugs
0
Clinical candidates (approved and in development)
1
- Approved drugs
- 0
- Clinical candidates (approved and in development)
- 1
- Chemical probe available
- No
- Target name
- IL1RL1
- Gene name
- Interleukin 1 receptor like 1
- Gene symbol
- IL1RL1
- Protein name
- Interleukin-1 receptor-like 1 (EC 3.2.2.6) (Protein ST2)
- ST2
- FIT-1
- ST2L
- ST2V
- DER4
- T1
- IL33R
- Gene biotype
- Protein coding
- Gene family
- I-set domain containing|Interleukin receptors|TIR domain containing
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 39
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 134.57
- Tissue specificity (Gini)
- 0.733
- Tissue specificity (tau)
- 0.969
- KEGG gene identifiers
- hsa:9173
- Protein interaction confidence
- 0.855688
- Protein interaction partners
- 16
- R-HSA-1257604
- R-HSA-6811558
- R-HSA-9014843
- End position
- 102352353
- Start position
- 102311502
- Chromosome
- 2
- Strand
- Forward
- [Isoform C]: Cell membrane.
- SUBCELLULAR LOCATION: [Isoform B]: Secreted.
- SUBCELLULAR LOCATION: Cell membrane
- Single-pass type I membrane protein .
- Cytosol
- Focal adhesion sites
- Plasma membrane
Publication evidence
- PubMed 11478810
- Tissue specificity (tau)
- 0.968879
- Expression inequality (Gini)
- 0.733199
Expression in transcripts per million
- Lung
- 134.57
- Kidney - Cortex
- 51.26
- Adrenal Gland
- 17.64
- Kidney - Medulla
- 15.5
- Adipose - Visceral (Omentum)
- 13.39
Expression in transcripts per million
- Lung134.57
- Kidney - Cortex51.26
- Adrenal Gland17.64
- Kidney - Medulla15.5
- Adipose - Visceral (Omentum)13.39
- Stomach12.24
- Adipose - Subcutaneous8.96
- Heart - Atrial Appendage6.88
- Breast - Mammary Tissue6.44
- Small Intestine - Terminal Ileum6.07
- Bladder4.93
- Esophagus - Gastroesophageal Junction3.9
- Esophagus - Muscularis3.9
- Artery - Coronary3.78
- Artery - Aorta3.62
- Skin - Sun Exposed (Lower leg)3.61
- Heart - Left Ventricle3.53
- Cells - Cultured fibroblasts3.41
- Fallopian Tube3.25
- Thyroid2.94
- Prostate2.94
- Nerve - Tibial2.88
- Vagina2.86
- Uterus2.8
- Colon - Transverse2.72
And 29 more, listed on the interactive page.
- GO:0007165
- GO:0038172
Cellular components
- GO:0005886
- GO:0002114
- GO:0004896
- GO:0005515
Related records
Trials (10)
- A First-in-Human, Double Blind, Single Dose Study in Healthy Subjects and Subjects With Mild Atopic Asthma.
- A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic Dermatitis
- A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe Asthma
- A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
- A Study to Evaluate the Effect of Injection Site on PK of Astegolimab in Healthy Subjects
- A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
- A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
- A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Chronic Rhinosinusitis With Nasal Polyps
- Anti-ST2 (MSTT1041A) in COPD (COPD-ST2OP)
Drugs (1)
- Astegolimab IL-33 receptor (ST2) inhibitor